Variantyx announced it has entered into a licensing agreement with IBM. Leveraging IBM’s artificial intelligence (AI) for somatic analysis, Variantyx intends to develop a comprehensive tumor diagnostic solution for the treatment of pediatric and adult neurological disorders and rare, undiagnosed diseases.
Menu
